Arvinas (NASDAQ:ARVN) Price Target Raised to $45.00 at Oppenheimer

Arvinas (NASDAQ:ARVN) had its price objective increased by Oppenheimer from $40.00 to $45.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other analysts also recently issued research reports about the stock. Guggenheim reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a research report on Wednesday. Barclays lowered their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. BMO Capital Markets restated an “outperform” rating and set a $82.00 target price (down from $88.00) on shares of Arvinas in a research note on Wednesday. Finally, Stifel Nicolaus cut their price target on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $59.58.

Arvinas Trading Up 1.5 %

Shares of NASDAQ ARVN opened at $17.95 on Wednesday. The stock has a fifty day moving average price of $19.18 and a 200 day moving average price of $23.32. Arvinas has a 12-month low of $16.61 and a 12-month high of $53.08. The company has a market cap of $1.23 billion, a P/E ratio of -3.84 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. During the same period in the previous year, the company posted ($2.53) earnings per share. On average, sell-side analysts forecast that Arvinas will post -3.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares in the last quarter. Rhumbline Advisers increased its stake in Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company’s stock valued at $1,685,000 after purchasing an additional 754 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Arvinas by 0.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after purchasing an additional 777 shares during the period. KBC Group NV lifted its position in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Arvinas by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after buying an additional 1,367 shares during the last quarter. Institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.